Bhakti Mehta

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières et al. · The Lancet · 2023 · 507 citations · Full text

Non-small-cell Lung Cancer, Medicine, Pathology +8

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Uwe Platzbecker, Argiris Symeonidis, Esther Natalie Olíva et al. · Leukemia · 2017 · 126 citations · Full text

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial

Hagop M. Kantarjian, Pierre Fenaux, Mikkael A. Sekeres et al. · The Lancet Haematology · 2018 · 100 citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +10

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Farhad Ravandi, Anthony S. Stein, Hagop M. Kantarjian et al. · Blood · 2018 · 80 citations

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<scp>ITP</scp>) for up to 1 year and in those with chronic <scp>ITP</scp> for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies

David J. Kuter, Adrian C. Newland, Beng H. Chong et al. · British Journal of Haematology · 2019 · 64 citations · Full text